A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

Completed · Phase 3 · Has a placebo group

Conditions studied: Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis

In brief

This is a study to compare the efficacy of bimekizumab versus secukinumab in subjects with moderate to severe chronic plaque psoriasis (PSO).

Key facts

Study ID

NCT03536884

Run by

UCB Biopharma SRL

People needed

743

Starts

2018-06-13

Expected to finish

2023-08-09

Last updated by the study team

2026-04-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Double-blind Treatment Period
• Male or female at least 18 years of age
• Subject must have had chronic plaque psoriasis (PSO) for at least 6 months prior to the Screening visit
• Subject must have Psoriasis Area Severity Index (PASI) >=12 and body surface area (BSA) affected by PSO >=10% and Investigator's Global Assessment (IGA) score >=3 on a 5 point scale
• Subject must be a candidate for systemic PSO therapy and/or phototherapy
• Subject must be considered, in the opinion of the Investigator, to be a suitable candidate for treatment with secukinumab per regional labeling and has no contraindications to receive secukinumab as per the local label
• Female subject of childbearing potential must be willing to use highly effective method of contraception
• Open-label extension (OLE) Period
• Completed the double-blind Treatment Period without meeting any withdrawal criteria
• All Week 48 visit assessments completed
• Compliant with ongoing clinical study requirements
• Signed a separate OLE Period Informed Consent Form (ICF)
• Female subject of childbearing potential must be willing to use highly effective method of contraception
• OLE2 Period (USA and Canada)
• Completed the OLE Period without meeting any withdrawal criteria
• Compliant with ongoing clinical study requirements
• Female subject of childbearing potential must be willing to use highly effective method of contraception
• Subjects with a diagnosis of Crohn's disease or ulcerative colitis are allowed as long as they have no active symptomatic disease (US only)
• Signed a separate OLE2 Period ICF

You may not qualify if…

• Double-blind Treatment Period
• Subject has an active infection (except common cold), a serious infection, or a history of opportunistic, recurrent or chronic infections
• Subject has concurrent acute or chronic viral hepatitis B or C or human immunodeficiency virus (HIV) infection
• Subject has known tuberculosis (TB) infection, is at high risk of acquiring TB infection, or has current or history of nontuberculous mycobacterium (NTMB) infection
• Subject has any other condition, including medical or psychiatric, which, in the Investigator's judgment, would make the subject unsuitable for inclusion in the study
• Presence of active suicidal ideation or severe depression
• Subject has any active malignancy or history of malignancy within 5 years prior to the Screening Visit EXCEPT treated and considered cured cutaneous squamous or basal cell carcinoma, or in situ cervical cancer
• OLE2 Period (USA and Canada)
• Subject has developed any medical or psychiatric condition, which, in the Investigator's judgment, would make the subject unsuitable for inclusion in OLE2 Period
• Subject had a positive or indeterminate interferon-gamma release assay (IGRA) in the OLE study to Week 144, unless appropriately evaluated and treated
• Presence of active suicidal ideation or severe depression
• Subject has developed any active malignancy or history of malignancy prior to the OLE2 Screening Visit EXCEPT treated and considered cured cutaneous squamous or basal cell carcinoma, or in situ cervical cancer

Where it is running

• Ps0015 939 — Danbury, Connecticut, United States
• Ps0015 903 — Ocala, Florida, United States
• Ps0015 921 — Ormond Beach, Florida, United States
• Ps0015 977 — Pembroke Pines, Florida, United States
• Ps0015 936 — Tampa, Florida, United States
• Ps0015 976 — Tampa, Florida, United States
• Ps0015 970 — West Palm Beach, Florida, United States
• Ps0015 966 — Sandy Springs, Georgia, United States
• Ps0015 954 — Skokie, Illinois, United States
• Ps0015 972 — West Dundee, Illinois, United States
• Ps0015 900 — West Des Moines, Iowa, United States
• Ps0015 944 — New Orleans, Louisiana, United States
• Ps0015 915 — Clayton, Missouri, United States
• Ps0015 953 — St Louis, Missouri, United States
• Ps0015 901 — Portsmouth, New Hampshire, United States
• Ps0015 965 — Kew Gardens, New York, United States
• Ps0015 969 — High Point, North Carolina, United States
• Ps0015 971 — Wilmington, North Carolina, United States
• Ps0015 980 — Bexley, Ohio, United States
• Ps0015 920 — Portland, Oregon, United States
• Ps0015 929 — Portland, Oregon, United States
• Ps0015 979 — Dallas, Texas, United States
• Ps0015 924 — Houston, Texas, United States
• Ps0015 978 — Pflugerville, Texas, United States
• Ps0015 975 — Santa Ana, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.